Product Name

  • Name

    CITRININ

  • EINECS
  • CAS No. 518-75-2
  • Article Data12
  • CAS DataBase
  • Density 1.37g/cm3
  • Solubility
  • Melting Point 175°C (dec.)
  • Formula C13H14 O5
  • Boiling Point 440.6°Cat760mmHg
  • Molecular Weight 250.251
  • Flash Point 170.2°C
  • Transport Information
  • Appearance yellow crystalline powder or flakes
  • Safety Poison by ingestion and other routes. An experimental teratogen. Other experimental reproductive effects. A severe skin irritant. Questionable carcinogen with experimental neoplastigenic and tumorigenic data. Mutation data reported. When heated to decomposition it emits acrid smoke and irritating fumes.
  • Risk Codes 23/24/25-40-36/37/38
  • Molecular Structure Molecular Structure of 518-75-2 (CITRININ)
  • Hazard Symbols T
  • Synonyms 3H-2-Benzopyran-7-carboxylicacid, 4,6-dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-, (3R-trans)-; Citrinin(6CI); (-)-Citrinin;4,6-Dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-3H-2-benzopyran-7-carboxylic acid;NSC 186
  • PSA 83.83000
  • LogP 1.72100

CITRININ Chemical Properties

Product Name: Citrinin (CAS NO.518-75-2)


Molecular Formula: C13H14O5
Molecular Weight: 250.25g/mol
Mol File: 518-75-2.mol
Einecs: 208-257-2
Appearance: Yellow crystalline powder or flakes
Melting Point: 175°C (dec.)
Boiling point: 409.8 °C at 760 mmHg
Storage Temperature: 2-8°C
Flash Point: 156.6 °C
Density: 1.37 g/cm3
Surface Tension: 55.9 dyne/cm
Enthalpy of Vaporization: 76.5 kJ/mol
Vapour Pressure: 1.99E-08 mmHg at 25°C
Product Categories: Active Pharmaceutical Ingredients

CITRININ Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
guinea pig LD50 subcutaneous 37mg/kg (37mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION Journal of Pharmacology and Experimental Therapeutics. Vol. 88, Pg. 173, 1946.
hamster LD50 intraperitoneal 66mg/kg (66mg/kg)   Food and Cosmetics Toxicology. Vol. 16, Pg. 355, 1978.
hamster LD50 oral 75mg/kg (75mg/kg)   Food and Cosmetics Toxicology. Vol. 16, Pg. 355, 1978.
mouse LD50 intraperitoneal 35mg/kg (35mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION Journal of Pharmacology and Experimental Therapeutics. Vol. 88, Pg. 173, 1946.
mouse LD50 oral 112mg/kg (112mg/kg)   Toxicology and Applied Pharmacology. Vol. 37, Pg. 139, 1976.
mouse LD50 subcutaneous 73mg/kg (73mg/kg)   Food and Cosmetics Toxicology. Vol. 15, Pg. 29, 1977.
rabbit LD50 intraperitoneal 50mg/kg (50mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
Food and Chemical Toxicology. Vol. 21, Pg. 487, 1983.
rabbit LD50 intravenous 19mg/kg (19mg/kg) SENSE ORGANS AND SPECIAL SENSES: MIOSIS (PUPILLARY CONSTRICTION): EYE

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Journal of Pharmacology and Experimental Therapeutics. Vol. 88, Pg. 173, 1946.
rabbit LD50 oral 134mg/kg (134mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
Food and Chemical Toxicology. Vol. 21, Pg. 487, 1983.
rat LD50 intraperitoneal 50mg/kg (50mg/kg)   Pharmaceutical Bulletin. Vol. 3, Pg. 337, 1955.
rat LD50 subcutaneous 67mg/kg (67mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION

BLOOD: OTHER CHANGES
Journal of Pharmacology and Experimental Therapeutics. Vol. 88, Pg. 173, 1946.

CITRININ Consensus Reports

IARC Cancer Review: Group 3 IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 , 1987,p. 56.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) , Animal Limited Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 40 , 1986,p. 67.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210)

CITRININ Safety Profile

Poison by ingestion and other routes. An experimental teratogen. Other experimental reproductive effects. A severe skin irritant. Questionable carcinogen with experimental neoplastigenic and tumorigenic data. Mutation data reported. When heated to decomposition it emits acrid smoke and irritating fumes.
Safety Information of Citrinin (CAS NO.518-75-2):
Hazard Codes: T
Risk Statements: 23/24/25-40-36/37/38 
23:  Toxic by inhalation 
24:  Toxic in contact with skin 
25:  Toxic if swallowed 
36:  Irritating to the eyes 
37:  Irritating to the respiratory system 
38:  Irritating to the skin  
40:  Limited evidence of a carcinogenic effect 
Safety Statements: 26-36/37/39-45-22-7/9
7:  Keep container tightly closed 
9:  Keep container in a well-ventilated place
22:  Do not breathe dust
26:  In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
36:  Wear suitable protective clothing  
37:  Wear suitable gloves  
39:  Wear eye/face protection 
45:  In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)

CITRININ Specification

 Citrinin ,its CAS NO. is 518-75-2,the synonyms is Antimycin ; Cit ; Citrinin, penicillium citrinum ; 4,6-Dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-3h-2-benzopyran-7-carboxylic ; 4,6-Dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-3h-2-benzopyran-7-carboxylic acid ; (3r,4s)-4,6-Dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-3h-2-benzopyran-7-carbox ; (3r,4s)-4,6-Dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-3h-2-benzopyran-7-carboxylic acid .

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View